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Abstract
Background: Nevirapine (NVP) is widely used in antiretroviral treatment (ART) of HIV-1 globally. The primary objective
of the AA5208/OCTANE trial was to compare the efficacy of NVP-based versus lopinavir/ritonavir (LPV/r)-based initial
ART.
Methods and Findings: In seven African countries (Botswana, Kenya, Malawi, South Africa, Uganda, Zambia, and
Zimbabwe), 500 antiretroviral-naı¨ve HIV-infected women with CD4,200 cells/mm3 were enrolled into a two-arm
randomized trial to initiate open-label ART with tenofovir (TDF)/emtricitabine (FTC) once/day plus either NVP (n = 249)
or LPV/r (n = 251) twice/day, and followed for $48 weeks. The primary endpoint was time from randomization to death
or confirmed virologic failure ([VF]) (plasma HIV RNA,1 log10 below baseline 12 weeks after treatment initiation, or
$400 copies/ml at or after 24 weeks), with comparison between treatments based on hazard ratios (HRs) in intention-
to-treat analysis. Equivalence of randomized treatments was defined as finding the 95% CI for HR for virological failure
or death in the range 0.5 to 2.0. Baseline characteristics were (median): age = 34 years, CD4 = 121 cells/mm3, HIV
RNA = 5.2 log10copies/ml. Median follow-up = 118 weeks; 29 (6%) women were lost to follow-up. 42 women (37 VFs,
five deaths; 17%) in the NVP and 50 (43 VFs, seven deaths; 20%) in the LPV/r arm reached the primary endpoint (HR
0.85, 95% CI 0.56–1.29). During initial assigned treatment, 14% and 16% of women receiving NVP and LPV/r
experienced grade 3/4 signs/symptoms and 26% and 22% experienced grade 3/4 laboratory abnormalities. However,
35 (14%) women discontinued NVP because of adverse events, most in the first 8 weeks, versus none for LPV/r
(p,0.001). VF, death, or permanent treatment discontinuation occurred in 80 (32%) of NVP and 54 (22%) of LPV/r arms
(HR = 1.7, 95% CI 1.2–2.4), with the difference primarily due to more treatment discontinuation in the NVP arm. 13
(45%) of 29 women tested in the NVP versus six (15%) of 40 in the LPV/r arm had any drug resistance mutation at time
of VF.
Conclusions: Initial ART with NVP+TDF/FTC demonstrated equivalent virologic efficacy but higher rates of treatment
discontinuation and new drug resistance compared with LPV/r+TDF/FTC in antiretroviral-naı¨ve women with CD4,200 cells/
mm3.
Trial registration: ClinicalTrials.gov NCT00089505
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Introduction
Most of the 33 million people living with HIV reside in
resource-limited settings (RLS), and more than 5 million are
receiving antiretroviral treatment (with the number treated
continuing to increase). Globally, the vast majority of antiretroviral
treatment (ART) is provided by general practitioners (and not
HIV specialists), using a public health approach. One of the
primary ART regimens recommended in 2010 by the World
Health Organization (WHO) for initial treatment of HIV-infected
persons is composed of tenofovir (TDF), emtricitabine (FTC), and
nevirapine (NVP) [1]. This particular combination is rapidly
becoming one of the most commonly used antiretroviral treatment
regimens worldwide, particularly among women. However,
minimal data regarding the efficacy of this combination exist.
Furthermore, many practitioners have expressed concern about
the potency of this particular regimen, given early data emanating
from small studies and observational cohorts suggesting possible
suboptimal efficacy [2,3]. In addition, the efficacy and toxicity of
initial ART containing NVP have not been compared prospec-
tively with regimens containing lopinavir/ritonavir (LPV/r), the
most commonly available boosted protease inhibitor (PI) in RLS at
this time. If initial ART with a PI such as LPV/r were found to be
much more effective or better tolerated than ART with the
commonly used NVP-based regimens, then first-line treatment
with a PI could in fact be cost-effective [4]; conversely equivalence
of NVP and LPV/r would provide some reassurance regarding
NVP-based ART as an initial therapy as recommended by WHO
guidelines. Rigorous data regarding the efficacy (and comparative
efficacy) of recommended and frequently used ART regimens is of
vital importance to HIV programs worldwide.
A particular concern among women starting ART is that prior
exposure to single dose NVP (sdNVP) during labor for preventing
mother-to-child transmission (PMTCT) of HIV may affect the
relative efficacy of these two regimens. We therefore conducted
A5208/OCTANE, a study consisting of two parallel randomized
trials of initial three-drug ART that included LPV/r versus NVP
among women in Africa. For one trial among women with prior
sdNVP exposure, we previously reported the superior efficacy of
LPV/r versus NVP [5]. In this report, we present the results from
women without prior sdNVP exposure.
Methods
Ethics
The study was approved by all overseeing local Institutional
Review Boards (IRBs)/Ethics Committees, as well as IRBs at the
following US institutions: Harvard School of Public Health,
Walter Reed Army Institute of Research, Indiana University,
University of North Carolina, Case Western Reserve University,
University of Alabama, and University of California San Diego.
Participants provided written informed consent.
Study Design, Participants
OCTANE comprised two concurrent, randomized open-label
ART trials (see Texts S1 and S2 for trial details). Trial 1 was
conducted among 243 women who had ingested sdNVP $6 mo
prior to enrollment (results published [5]), and was designed to test
the superiority of LPV/r over NVP due to the hypothesis that
prior sdNVP exposure would result in persistent NVP drug
resistance. Trial 2, described in this report, was conducted among
502 women without prior sdNVP exposure. Trial 2 was designed
to test the equivalence of LPV/r with NVP on the basis of the
hypothesis that the efficacy of NVP- and LPV/r-based ART
would be similar. To permit optimal interpretation of trial 1,
interim trial 2 virologic failure (VF)/death results after partial
follow-up (through 6 October 2008) were included in the
published trial 1 paper [5]. This current report describes detailed
and final trial 2 results, using data from a substantially longer
period of follow-up (through 30 September 2009).
Participants were consenting, HIV-1-infected adult women who
were not pregnant or breastfeeding, from ten African sites (three in
South Africa; two in Kenya; and one each in Zimbabwe,
Botswana, Zambia, Malawi, and Uganda). Participants had
screening CD4+ cell count (CD4),200 cells/mm3 and trial 2
participants were antiretroviral-naı¨ve, except that up to 10 wk of
prior zidovudine (ZDV) were permitted (as short-course ZDV was
included in mother-to-child HIV transmission prevention regi-
mens in some countries, and is not associated with significant
development of major drug resistance mutations). Lack of prior
sdNVP exposure was based on participant recall and self-report, in
combination with one or more of the following when available: no
prior pregnancy or pregnancy prior to the use of sdNVP in
country; HIV diagnosis after pregnancy; pre-delivery/postpartum
or other relevant records reviewed and no sdNVP recorded;
patient confirmation of no prior sdNVP after being shown tablet.
Additional eligibility criteria included estimated creatinine clear-
ance $60 ml/minute; hemoglobin $7.0 g/dl; absolute neutrophil
count $750 cells/mm3; alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase, and total bilirubin
(each #2.5 times the upper limit of normal); absence of
pregnancy/breastfeeding; absence of serious illness or tuberculosis
treatment within the prior 30 d; and Karnofsky score $70.
Participants were followed until 48 wk after the last enrollment.
Women were randomized to open-label LPV/r (400 mg/
100 mg) one capsule (or tablet) twice daily plus TDF/FTC
(300 mg/200 mg) one tablet once daily; or to NVP 200 mg twice
daily plus TDF/FTC 300/200 mg once daily (after 14-d lead-in
with NVP 200 mg once daily). TDF/FTC was co-formulated in
Truvada. LPV/r was initially supplied as Kaletra capsules, then
heat-stable Aluvia tablets. Participants could switch from NVP to
second-line treatment with LPV/r or vice versa (and ZDV and
didanosine were provided), in cases of VF (at the discretion of local
investigators/participants) or toxicity. EFV was temporarily
substituted for NVP and LPV/r during rifampin-containing
tuberculosis treatment. Randomization was computer-generated
using balanced block randomization (block size 4) stratified by
screening CD4 count (, or $50 cells/mm3). Randomized
assignment was provided electronically from a remote, central
Data Management Center in the US back to each clinical site.
While the study was being conducted, access to the block size and
the sequence of treatment assignments was restricted to Data
Center staff who set up the randomization.
Data Collection, Follow-up, and Laboratory Analyses
Study visits (with safety laboratory/clinical assessment) occurred
at 2, 4, 8, 12, 16, and 24 wk after treatment initiation and every
12 wk thereafter. HIV-1 RNA (Roche Amplicor Monitor V1.5)
and CD4 were assessed at entry, then every 12 wk. Lipids (fasting
or non-fasting) were evaluated at entry, 24, and 48 wk, then every
48 wk.
A random subgroup of 126 pre-therapy samples were tested for
HIV-1 drug resistance using the ViroSeq HIV-1 Genotyping
System (V2.0), with data analyzed using ViroSeq Genotyping
Software V2.7 (both Celera Diagnostics). In addition, pre-therapy
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and time-of-failure samples were tested from all patients experi-
encing virologic failure.
Protocol-Specified Toxicity Management
ART was generally held in the event of potentially treatment-
related grade $3 toxicity. However, more conservative toxicity
management was followed for suspected NVP or TDF toxicity.
Specifically, the presence of any of the following in combination
with any rash (and no other clear explanation) required permanent
discontinuation of NVP: systemic, allergic, or mucosal symptoms;
or elevated ALT, AST, creatinine, or eosinophils. NVP was also
permanently discontinued in participants experiencing grade $2
elevations in ALT or AST (or with worsening of LFTs by $1
grade in combination with hepatitis signs/symptoms). TDF was
permanently discontinued if confirmed estimated creatinine
clearance decreased to,50 ml/min, in absence of alternate cause.
Women becoming pregnant after enrollment were continued on
study treatment, with ZDV substituted for TDF during pregnancy
unless a contraindication to ZDV existed.
Statistical Analysis
The primary endpoint was time to VF or death. VF was defined
as plasma HIV-1 RNA,1 log10 copies/ml below baseline 12 wk
after treatment initiation, or HIV-1 RNA $400 copies/ml at
$24 wk after initiation; in both cases with confirmation by a
second measurement meeting the respective criterion.
The primary analysis was intention to treat, including all follow-
up irrespective of changes in ART (but excluded women failing to
start study treatment, per protocol). Trial 2 was designed to
evaluate the equivalence of LPV/r- and NVP-based therapies:
equivalence was to be established if the two-sided 95% CI for the
hazard ratio (HR) for VF/death was entirely within the range 0.5–
2.0.
The Kaplan-Meier method was used to describe the cumulative
proportion of participants experiencing VF or death by time. Cox
proportional hazards models, stratified by screening CD4 (,50
versus$50 cells/mm3), were used to estimate the HR (95% CIs) of
reaching an endpoint comparing arms.
In secondary analysis, we also evaluated equivalence at each of
week 48, 96, and 144 with respect to the absolute difference
between randomized treatments in the Kaplan-Meier estimate of
the percentage of subjects reaching an endpoint by these times, on
the basis of the common definition that the 95% CI for the
absolute difference was entirely within the range 210% to +10%.
Adjusted analyses were undertaken by including each of the
following variables in turn into the proportional hazards model,
which also included randomized treatment: existence or not of
written documentation of no prior sdNVP exposure, prior ZDV
use, site, and baseline age, CD4 count, HIV-1 RNA, and WHO
stage. Subgroup analyses were undertaken by also including the
treatment interaction with each of these variables in the model.
These variables were pre-specified in the analysis plan prior to the
first interim analysis.
Discontinuation of initial assigned regimen was defined as
permanent discontinuation of either LPV/r or NVP. In secondary
as-treated analysis, VF was considered to have occurred on the
randomized regimen only if the initial failing HIV-1 RNA
measurement was obtained on or before the day of last dose of
the initial regimen. Analyses of adverse events (AEs) were
restricted to the period during which participants received initial
NVP or LPV/r. Linear regression was used to compare changes in
CD4 count and lipids, adjusted for baseline count/level.
The original planned sample size for trial 2 was 400. During
closed reviews by an independent Data and Safety Monitoring
Board (DSMB), it was noted that the proportion of women
experiencing a primary endpoint might be lower than anticipated
(14% versus anticipated 20% with median follow-up of 72 wk).
The sample size was therefore increased to 500, which, with an
associated increase in expected median follow-up to 108 wk, was
expected to provide about 77% probability of completing the
study showing equivalence (95% CI for the primary endpoint HR
entirely within the range 0.5–2.0) assuming no true difference
between treatments.
Review by the DSMB occurred every 6–12 mo. The protocol
stated that early termination of the trial for efficacy would
generally only be considered if equivalence was established to a
very high level of evidence, specifically a 99.9% CI unadjusted for
interim analyses within the narrow range of 0.75–1.33, or if a
difference between randomized arms was established with
substantial evidence, specifically a 99.9% CI excluding a HR of
one; because trial 2 was not stopped early, standard 95% CIs can
therefore be used at the end of the study [6]. p-Values are two-
sided, for the test of no difference between randomized treatments.
Results
A total of 502 women (target 500) enrolled and were
randomized to NVP+TDF/FTC versus LPV/r+TDF/FTC from
November 2005–July 2008 (37–81 participants/site) (Figure 1).
Two women (in the NVP arm) never started study treatment and
were excluded from all analyses. Therefore, results from 500
women (249 randomized to receive NVP, 251 to LPV/r) were
included. One participant had previously taken sdNVP but was
mistakenly enrolled (in the LPV/r arm); her data are included.
Median age, CD4 count, and HIV-1 RNA at baseline were
34 y, 121 cells/mm3, and 5.2 log10 copies/ml, respectively
(Table 1), and were similar in both arms. Evidence (in addition
to self-report) for lack of prior exposure to sdNVP was available for
469 (94%) women (most commonly, no pregnancy or occurrence
of pregnancy prior to local use of sdNVP [n=272] or HIV
diagnosis after pregnancy [n=168]). Seven (1%) women reported
prior ZDV for preventing mother-to-child transmission. Of the
random sample of 126 pre-therapy samples tested for HIV-1 drug
resistance (60 from the NVP and 66 from the LPV/r arms),
baseline NVP resistance (K103N) was detected in only one (0.8%)
sample (Table 1). No nucleoside analog reverse-transcriptase
inhibitor (NRTI) or major protease-resistance mutations were
detected at baseline, although minor protease-resistance mutations
were present in 100% of samples. Subtype C virus was found in 85
(71%).
20 women (4%; 14 assigned to NVP and six to LPV/r) were lost
to follow-up without first experiencing a primary endpoint
(p=0.08). Nine additional women were lost to follow-up after
experiencing VF (two in the NVP and seven in the LPV/r arms),
leading to overall loss to follow-up of 6%. The median duration of
follow-up on initial assigned treatment was 109 wk (95 wk in the
NVP and 119 wk in the LPV/r arms), and the overall median
duration of follow-up in the study was 118 wk. At each scheduled
evaluation, completed adherence questionnaires were available for
$78% of participants. Adherence to initial study treatment was
lowest at week 24, when 84% of women reported not missing any
medications during the past month (88% versus 81% for the NVP
and LPV/r arms). Adherence was 87%–92% at all other weeks.
Primary Endpoint: VF or Death, Intent-to-Treat Analysis
HIV-1 RNA results were available from 99.6% of 4,223
expected time points. 92 (18%) women either experienced VF or
died without prior VF, including 42 (17%) assigned to NVP and
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50 (20%) to LPV/r (HR 0.85, 95% CI 0.56–1.29, p=0.43)
(Figure 2). This group included 37 (15%) and 43 (17%) women in
the NVP and LPV/r arms, respectively, who experienced VF; and
five (2%) and seven (3%) in the NVP and LPV/r arms,
respectively, who died without prior VF (one additional woman
died following confirmed VF). There was no significant evidence
that the HR for the primary endpoint changed with increasing
follow-up time (p=0.58).
Based on the 95% CI for the HR (0.56–1.29), the NVP- and
LPV/r-based regimens showed equivalent efficacy for the
endpoint of VF or death according to the pre-specified criterion.
The estimated percentage of women experiencing VF/death by
week 48 was 14.3% with NVP and 13.7% with LPV/r (absolute
difference = 0.6%). The associated 95% CI (25.5% to 6.8%) was
entirely within the range 210% to +10%. The corresponding
results in the NVP and LPV/r arms, respectively, were 16.5% and
19.6% (difference: 23.1%; 95% CI 210.2% to 4.0%) at week 96,
and 19.1% and 25.3% (difference: 26.2%; 95% CI 215.0% to
2.7%) at week 144.
The primary cause of death in the five women in the NVP arm
was tuberculosis, pneumonia, acute renal failure, pulmonary
embolus, and unknown (the last patient had headache and prior
renal failure and pleural effusion). The death from acute renal
failure (but no other deaths in the NVP arm) was deemed probably
related to study treatment. Among the eight women in the LPV/r
arm who died, three deaths (due to acute renal failure, severe
gastroenteritis, and hepatic encephalopathy) were considered
possibly related to study treatment. The cause of death in the
other five women in the LPV/r arm was gastroenteritis,
progressive HIV disease, central nervous system lymphoma,
bacterial septicemia, and unknown in one woman.
19 (8%) of the women in the NVP arm experienced disease
progression (to a higher WHO stage) or died, compared with 26
(10%) in the LPV/r arm (p=0.30).
Adjusted and Subgroup Analyses
The adjusted HRs for the primary endpoint comparing NVP- to
LPV/r-based treatment in the whole study population varied
between 0.83–0.86 (versus an unadjusted HR=0.85) and the
associated 95% CIs all remained within the range 0.50–2.00.
Baseline HIV-1 RNA was the only tested variable that was
predictive of reaching a primary endpoint, after controlling for
randomized regimen (for each log10 copies/ml increase: HR 1.56,
95% CI 1.07–2.28).
In subgroup analyses, the only significant finding (interaction
p,0.05) was for CD4. Specifically, among women with CD4#100
cells/mm3 (the median for participants reaching a primary
endpoint), 26 (27%) of 96 assigned to NVP versus 19 (21%) of
90 assigned to LPV/r experienced a primary endpoint (HR 1.36,
95% CI 0.74–2.51). In contrast, for women with baseline
Figure 1. Consort diagram. Per protocol, participants were not mandated to switch regimens in instances of VF (this decision was left to the
discretion of study staff and participants). More women experienced VF in the LPV/r arm (43 or 17%) compared with the NVP arm (37 or 15%) in ITT
analysis; however, a higher proportion of women experiencing VF in the NVP arm were switched to LPV/r compared with vice versa.
doi:10.1371/journal.pmed.1001236.g001
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CD4.100 cell/mm3, the numbers were 16 (11%) of 153 and 31
(19%) of 161, respectively (HR 0.55, 95% CI 0.30–1.01) (p=0.034
for interaction).
VF or Death, As-Treated Analysis
In the as-treated analysis, 30 (12%) women in the NVP arm and
48 (19%) in the LPV/r arm experienced a primary endpoint (HR
0.71, 95% CI 0.45–1.13). The proportions of women in the NVP
versus LPV/r arms experiencing a primary endpoint in the as-
treated analysis were 12.2% versus 13.4% at 48 wk (difference:
21.2%; 95% CI27.3% to 4.9%), 13.6% versus 18.8% at week 96
(difference: 25.2%; 95% CI 212.2 to 1.9%), and 15.5% versus
24.5% at week 144 (difference: 29.1%; 95% CI 217.8% to
20.4%).
Discontinuation of NVP or LPV/r for Any Reason
93 women discontinued their initial randomized regimen—
significantly more women in the NVP (70, 28%) compared with
the LPV/r (23, 9%) arm (HR 3.45, 95% CI 2.15–5.52, p,0.001)
(Figure 3).
The reasons for discontinuation from NVP-based treatment
included death (n=5), AEs (n=35), VF (n=15), and other reasons
(n=15). Among the 35 women discontinuing NVP due to AEs, 20
did so following hepatic events, three following the development of
both a hepatic event and a rash, and 12 following rashes (77% of
these 35 women discontinued NVP during the first 8 wk on
treatment). For all 35 women, the site investigators considered the
association of the AE to be potentially related to study treatment.
The reasons for discontinuation from LPV/r-based treatment
included death (n=8), VF (n=4), and other reasons (n=11); no
women discontinued LPV/r due to an AE.
Therefore, more women discontinued NVP (compared with
LPV/r) in first line, because of either VF or to an AE, despite
similar numbers of participants experiencing primary endpoints or
grade 3 or higher AEs in both arms (described below). Only four of
the 43 women experiencing VF in the LPV/r arm discontinued
LPV/r for VF, compared with 15 of 37 women experiencing VF
in the NVP arm. The decision of whether or not to switch a
regimen when protocol-defined VF occurred was left to the site
investigator and participant, who usually elected to intensify
adherence counseling and support and continue the initial
regimen, with site clinicians being less likely to switch LPV/r
compared with NVP, following HIV-1 RNA.400 cp/ml occur-
ring on treatment.
Table 1. Selected characteristics of OCTANE trial 2 participants at baseline.
Characteristics Statistics Categories NVP (n=249) LPV/r (n=251) Total (n=500)
Age at randomization (y) Median (P10, P90) 35 (26, 44) 34 (25, 45) 34 (26, 45)
Race/ethnicitya Black 249 (100%) 251 (100%) 500 (100%)
Baseline CD4 count (cells/mm3) Median (P10, P90) 121 (40, 208) 121 (32, 201) 121 (38, 204)
,50cells/mm3 32 (13%) 36 (14%) 68 (14%)
$200 cells/mm3b 31 (12%) 27 (11%) 58 (12%)
HIV-1 RNA (log10 copies/ml) Median (P10, P90) 5.16 (4.16, $5.88) 5.15 (4.28, 5.82) 5.15 (4.21, 5.86)
HIV-1 RNA (copies/ml) $750,000 26 (10%) 22 (9%) 48 (10%)
WHO HIV stage Clinical stage I 97 (39%) 93 (37%) 190 (38%)
Clinical stage II 72 (29%) 67 (27%) 139 (28%)
Clinical stage III 73 (29%) 80 (32%) 153 (31%)
Clinical stage IV 7 (3%) 11 (4%) 18 (4%)
Hepatitis B surface antigen Positive 18 (7%) 17 (7%) 35 (7%)
Not tested at entry 0 2 2
Pre-entry ZDV (#10 wk) 4 (2%) 3 (1%) 7 (1%)
Participant’s self-report of prior
ingestion of sdNVP
Yes 0 1 (0.4%) 1 (0.2%)
Supporting evidence for lack of
prior sdNVP exposure
Yes 232 (93%) 237 (94%) 469 (94%)
Sequence results 60 66 126
HIV subtype A1 9 (16%) 12 (19%) 21 (18%)
A2 0 (0%) 1 (1%) 1 (1%)
C 42 (75%) 43 (68%) 85 (71%)
D 4 (7%) 4 (6%) 8 (7%)
G 1 (2%) 0 (0%) 1 (1%)
Complex recombination 0 (0%) 3 (5%) 3 (3%)
Tested/no result 4 3 7
Nevirapine resistance 1 (2%)c 0 1 (0.8%)
Percentages use number of participants with a result as the denominator.
aRace was collected as it could potentially be related to treatment response and was reported by the site investigators.
bAll women had screening CD4,200 cells/mm3, but at study entry, 58 women had CD4$200 cells/mm3.
cK103N.
doi:10.1371/journal.pmed.1001236.t001
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More women also discontinued NVP (compared with LPV/r)
because of a clinical or laboratory abnormality. As described
below, more women in the NVP arm experienced rash and/or
liver test abnormality, and the protocol-mandated threshold for
permanently discontinuing a study drug after the occurrence of
these events was lower in the NVP arm compared with the LPV/r
arm.
We also conducted a pre-specified analysis on the basis of a
treatment failure composite endpoint, defined as time to the first of
protocol-defined VF, death, or permanent discontinuation of
initial randomized regimen. In this analysis, 80 (32%) of the 249
women randomized to NVP reached the composite endpoint
compared with 54 (22%) of the 251 women randomized to LPV/r
(HR 1.68, 95% CI 1.18–2.40). The occurrence of significantly
more composite treatment failure endpoints among women in the
NVP arm was entirely due to a higher rate of treatment
discontinuation in the NVP arm (and not due to higher rates of
VF or death).
Changes in CD4 Cell Count
At least 98% of expected CD4 cell counts were obtained at each
scheduled measurement time. In intent-to-treat analyses, mean
change in CD4 was 183 cells/mm3 in each arm at week 48
(p=0.99), 245 for NVP versus 279 cells/mm3 for LPV/r at week
96 (p=0.045) and 303 for NVP versus 345 cells/mm3 for LPV/r
at week 144 (p=0.15).
Toxicity and Diagnoses Occurring during Initial Assigned
Treatment
75 (15%) of the 500 women experienced $grade 3 signs or
symptoms through the date of the last dose of initial study
treatment (Table 2): 34 (14%) in the NVP and 41 (16%) in the
LPV/r arms (seven and eight women, respectively, experienced
grade 4 signs/symptoms). 64 (26%) women in the NVP versus 54
(22%) in the LPV/r arm experienced $grade 3 laboratory
abnormalities. More women in the LPV/r arm had $grade 3
elevation in creatinine (eight versus two), while more women in the
NVP arm had $grade 3 elevation in liver function tests (18 versus
nine). At 24, 48, and 96 wk after entry, participants in the LPV/r
arm experienced significantly greater increases in total cholesterol
and in low-density lipoprotein (LDL) (but smaller increases in
high-density lipoprotein [HDL]) than participants in the NVP arm
(while triglycerides increased in women in the LPV/r arm but
decreased in women in the NVP arm) (Table 2).
25 women switched from NVP or LPV/r to EFV during
rifampin-containing tuberculosis treatment, including 14 assigned
NVP and 11 assigned LPV/r. 47 women became pregnant during
the study, including 21 assigned NVP and 26 assigned LPV/r
(Table 2).
Drug Resistance
HIV-1 drug resistance testing was attempted on samples from
pre-therapy and failure time points among the 80 participants
Figure 2. Kaplan-Meier plot of time to primary endpoint (VF or death) by randomized treatment arm.
doi:10.1371/journal.pmed.1001236.g002
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experiencing VF, with genotypes available for 69 baseline-failure
pairs (Table 3). Genotypes from time of VF revealed that 13 (45%)
of 29 women in NVP arm and six (15%) of 40 women in the LPV/
r arm had any resistance mutation (excluding minor PI mutations).
13 (45%) women in the NVP versus three (8%) women in the
LPV/r arm had $1 non-NRTI (NNRTI)-associated mutation at
VF, and nine (31%) versus five (13%) (respectively) had NRTI-
associated mutations (most often K65R and M184V). New
(compared to pre-therapy) minor protease mutations were
detected in five participants (two in the NVP and three in the
LPV/r arms); no major PI mutations were found.
Discussion
Among African treatment-naı¨ve women with CD4 count ,200
cells/mm3, initial ART with NVP+TDF/FTC showed equivalent
efficacy compared with LPV/r+TDF/FTC in intention-to-treat
analysis of the primary endpoint of VF or death (83% versus 80%
of women were alive and had not experienced VF after a median
follow-up of more than 2 y; HR 0.85, 95% CI 0.56–1.29, which
was within the pre-specified range of equivalence from 0.5 to 2.0).
Equivalence was not established in the as-treated analysis, with
lower rates of VF/death in the NVP arm compared with the
LPV/r arm (HR 0.71, 95% CI 0.45–1.13). However, significantly
more women discontinued NVP than LPV/r (28% versus 9%,
p,0.001) including 14% versus none due to AEs. Consequently,
analysis of overall regimen failure (VF, death, or discontinuation
due to AEs) revealed lower rates of these combined endpoints in
the LPV/r arm. The proportions of women experiencing $grade
3 signs, symptoms, or laboratory abnormalities did not differ
significantly between arms, but total cholesterol and triglyceride
increases were significantly larger in the LPV/r arm. Therefore,
the higher rate of permanent discontinuation of NVP was
primarily driven by protocol-mandated thresholds for permanent
discontinuation of NVP compared with LPV/r, rather than higher
rates of severe or life-threatening toxicities in the NVP arm.
Overall, these data support the WHO recommendation of NVP/
TDF/FTC as an initial affordable and effective HIV treatment
regimen in RLS, and provide reassurance regarding the efficacy of
this regimen. However, these results also underscore the impor-
tance of early toxicity monitoring with NVP-based regimens. The
treatment failure (due to VF or treatment discontinuation)
observed in both arms also highlights the importance of access
to effective second treatment options, as well as consideration of
other effective, better-tolerated first-line regimens (including
among women of reproductive potential).
Figure 3. Kaplan-Meier plot of time to early discontinuation of initial randomized treatment for any reason (toxicity, intolerance,
VF, death), by randomized treatment arm.
doi:10.1371/journal.pmed.1001236.g003
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The overall and relative efficacy and toxicity of NVP-based
versus PI-based ART are relevant in RLS. Globally, NVP is the
most frequently used antiretroviral in combination with two
NRTIs, due primarily to its low cost, lack of teratogenicity, and
heat stability; and regimens including TDF+NVP (with either
3TC or FTC) are recommended by the WHO and increasingly
used [1]. However, prior small studies of first-line ART
composed of NVP+TDF/FTC demonstrated rather high rates
of early VF on this regimen, raising concern about its use [2,3].
If LPV/r were found to be significantly more (or more durably)
potent or less toxic than NVP in first-line treatment, then it
could potentially represent a cost-effective choice for initial
regimen in RLS (as reported in a previous cost-effectiveness
analysis comparing these regimens among women with prior
sdNVP exposure [4]), although this has yet to be modeled in
ARV-naive patients. To our knowledge, this is the first direct
comparison of the efficacy of NVP- and LPV/r-based ART, and
one of only a small number of studies to compare the efficacy of
ART using NVP versus any boosted PI [7,8]. This is also one of
the largest randomized treatment trials to be conducted in HIV-
infected women, who may experience different toxicities or
response compared with men, but who are often underrepre-
sented in trials. In one previous study (‘‘ARTEN’’ [8]), 569
treatment-naive patients were randomized to initiate NVP or
atazanavir/ritonavir, each in combination with Truvada.
Similar proportions achieved virologic suppression with both
treatments, although more patients stopped treatment due to
AEs in the NVP (14%) than the atazanavir (4%) arm [8]. These
findings are qualitatively similar to the OCTANE Trial 2
results, but are in contrast to those of an observational
European study, in which patients were more likely to stop
first-line NVP because of treatment failure but less likely to do
so because of toxicity or patient/provider choice, compared
with EFV or LPV/r [7].
Table 2. Signs/symptoms, laboratory abnormalities, diagnoses, and lipid results among participants on their first randomized
treatment regimens.
Clinical/Laboratory Outcome NVP Arm (n=249) LPV/r Arm (n=251) Total (n=500) Unadjusted p-Value
Grade 3 or higher sign or symptom: 34 41 75
General body (pain, fatigue, weight loss, fever) 14 27 41
Gastrointestinal (diarrhea, nausea/vomiting) 5 5 10
Respiratory 4 6 10
Cardiovascular 3 3 6
Liver/hepatic 0 1 1
Skin 9 2 11
Neurological 7 6 13
Grade 3 or higher laboratory abnormality: 64 54 118
Creatininea 2 8 10
Chemistry (any abnormality) 15 18 33
Sodium 8 14 22
Potassium 2 1 3
Alkaline phosphatase 3 1 4
Liver/hepatic (any abnormality)a 18 9 27
SGOT 15 6 21
SGPT 16 7 23
Total bilirubin 2 3 5
Hematology (any abnormality) 37 30 67
Platelets 1 1 2
Hemoglobin 6 11 17
Absolute neutrophil count 31 21 52
Number of participants with new diagnoses 150 164 314
Number of participants with pregnancy on-study 21 26 47
Change in lipids from baseline to 48 wk
(mg/dl; standard error)
Total cholesterol 19 (62.3) 31 (62.2) 0.0008
HDL cholesterol 17 (61.3) 11 (60.9) ,0.0001
LDL cholesterol 6 (61.8) 16 (61.9) 0.0005
Triglycerides 219 (66.1) 24 (64.3) ,0.0001
Subcolumns may not add up to total number of signs/symptoms or laboratory abnormalities, as participants can experience more than one event.
aIn the NVP and LPV/r arms, respectively, three and 12 participants experienced grade 2 or higher creatinine elevation, and 34 and 19 of participants experienced grade
2 or higher liver test abnormalities.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.
doi:10.1371/journal.pmed.1001236.t002
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Genotype analysis in our study of samples at the time of failure
revealed NNRTI- or NRTI-resistance mutations in nearly one-
half of women in the NVP arm. This frequency of resistance is
lower than that reported in other studies of failure of initial therapy
[9–11], and may be related to more rapid regimen switch (in the
context of careful HIV-1 RNA monitoring) or to premature
discontinuation of therapy for suspected toxicity. In the LPV/r
arm, major PI resistance mutations were not detected at failure
(similar to findings from other studies of LPV/r [9,12]), and
NRTI-associated mutations were less frequent (13%) than in the
NVP arm (31%). The occurrence of the K65R mutation in 28% of
participants failing NVP+TDF/FTC is notable. These resistance
findings have implications for selection of first-line and subsequent
ART regimens to optimize long-term clinical outcomes and
reduce spread of drug resistance.
Strengths of our study included its randomized nature and very
high visit and data completeness. Limitations include the
possibility that some participants may have had previous sdNVP
exposure. However, the accuracy of our sdNVP exposure
ascertainment is supported by a low rate (0.8%) of baseline NVP
resistance, and by results from trial 1 (which demonstrated higher
rates of VF/death with NVP versus LPV/r treatment among
women with prior sdNVP exposure [5]). Subgroup analyses need
to be interpreted with caution given the number of subgroup
analyses considered; the one difference (between women with
higher versus lower CD4 counts) identified would not be
significant with adjustment for multiple comparisons and so could
plausibly be a chance finding. We could not compare long-term
morbidity and mortality between regimens because of the study
duration. This was an open-label trial, and the lack of blinding
constitutes another potential limitation. Finally, patient outcomes
in a closely monitored clinical trial setting, including ramifications
of toxicity, may be better than those expected in a routine
treatment setting in RLS.
We conclude that in antiretroviral-naı¨ve women with CD4
count ,200 cells/mm3, initial ART with LPV/r/TDF/FTC and
with NVP+TDF/FTC is equivalent in achieving and maintaining
virologic suppression and preventing mortality, but that treatment
cessation due to toxicity concerns, and drug resistance at the time
of VF, are higher with NVP-based ART. Our findings suggest that
NVP (with careful early toxicity monitoring) remains an accept-
able choice for first-line ART in RLS, until better tolerated and
potentially more efficacious regimens become accessible.
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Table 3. Summary of drug resistance mutations at time of virologic failure.
Variable n (%) NVP Arm, n=37a n (%) LPV/r Arm, n=43
Samples with VF events 37 43
Genotype available at VF 29 (78) 40 (93)
No sample available for testing 1 (3) 0 (0)
No sequence available (unable to amplify) 7 (19) 3 (7)
Samples with any mutation 13 (45) 6 (15)
Samples with NRTI-associated mutations 9 (31) 5 (13)
K65R 8 (28) 2 (5)
K70W 1 (3) 0 (0)
M184V 9 (31) 3 (8)
Thymidine-associated mutations 2 (7) 1 (3)
Samples with NVP or EFV mutations 13 (45) 3 (8)
K103N 4 (14) 1 (3)
V106A 2 (7) 0 (0)
V106M 4 (14) 1 (3)
V108I 4 (14) 1 (3)
Y181C 8 (28) 0 (0)
Y181I 1 (3) 0 (0)
Y188C 1 (3) 0 (0)
G190A 2 (7) 2 (5)
Samples with any new protease mutations 2 (5) 3
Major protease mutations 0 (0) 0 (0)
Minor protease mutationsb 2 (5) 3 (7)
Samples with .1 NRTI mutation 9 1
Samples with .1 NNRTI mutation 9 2
Samples with $1 NRTI+$1 NNRTI mutation 9 2
aPercent mutation per treatment arm calculated as the number of patients with mutation divided by number of patients with genotype results available.
bNew minor protease-resistance mutations detected for NVP arm were L10I/V and L63P and for LPV/r arm were K20R and K20M (data not shown).
doi:10.1371/journal.pmed.1001236.t003
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Editors’ Summary
Background. About 34 million people (mostly living in low-
or middle-income countries) are currently infected with HIV,
the virus that causes AIDS. HIV destroys CD4 lymphocytes
and other immune cells, leaving infected individuals suscep-
tible to other infections. Early in the AIDS epidemic, most
HIV-infected people died within 10 years of infection. Then,
in 1996, antiretroviral therapy (ART)—cocktails of drugs that
attack different parts of HIV—became available. For people
living in affluent countries, HIV/AIDS became a chronic
condition. But, because ART was expensive, for people living
in developing countries, HIV/AIDS remained a fatal illness. In
2006, the international community set a target of achieving
universal access to ART by 2010 and, although this target has
not been reached, by the end of 2010, 6.6 million of the
estimated 15 million people in need of ART in developing
countries were receiving one of the ART regimens recom-
mended by the World Health Organization (WHO) in its 2010
guidelines.
Why Was This Study Done? A widely used combination
for the initial treatment of HIV-infected people (particularly
women) in resource-limited settings is tenofovir and
emtricitabine (both nucleotide reverse transcriptase inhibi-
tors; reverse transcriptase is essential for HIV replication) and
nevirapine (NVP, a non-nucleoside reverse transcriptase
inhibitor). However, little is known about the efficacy of this
NVP-based ART combination. Moreover, its efficacy and
toxicity has not been compared with regimens containing
lopinavir/ritonavir (LPV/r). LPV/r, which inhibits the viral
protease that is essential for HIV replication, is available in
resource-limited settings but is usually reserved for second-
line treatment. LPV/r-based ART is more expensive than NVP-
based ART but if it were more effective or better tolerated
than NVP-based ART, then first-line treatment with LPV/r-
based ART might be cost-effective in resource-limited
settings. Conversely, evidence of the clinical equivalence of
NVP-based and LPV/r-based ART would provide support for
NVP-based ART as an initial therapy. In this randomized
equivalence trial, the researchers compare the efficacy and
toxicity of NVP-based and LVP/r-based initial therapy for HIV
infection among antiretroviral-naı¨ve African women. In a
randomized trial, patients are assigned different treatments
by the play of chance and followed to compare the effects of
these treatments; an equivalence trial asks whether the
effects of two treatments are statistically equivalent.
What Did the Researchers Do and Find? The researchers
followed 500 antiretroviral-naı¨ve HIV-infected women with a
low CD4 cell count living in seven African countries, half of
whom received NVP-based ART and half of whom received
LPV/r-based ART, for an average of 118 weeks and recorded
the time to virologic failure (the presence of virus in the
blood above pre-specified levels) or death among the
participants. Forty-two women in the NVP arm reached this
primary endpoint (37 virologic failures and five deaths)
compared to 50 women in the LPV/r arm (43 virologic
failures and seven deaths), a result that indicates equivalent
virologic efficacy according to preset statistical criteria.
During the initial assigned treatment, similar proportions of
women in both treatment arms developed serious drug-
related signs and symptoms and laboratory abnormalities.
However, whereas 14% of the women in the NVP arm
discontinued treatment because of adverse effects, none of
the women in the LPV/r arm discontinued treatment. Finally,
nearly half of the women tested in the NVP arm but only 15%
of the women tested in the LVP/r arm had developed any
drug resistance at the time of virologic failure.
What Do These Findings Mean? These findings indicate
that, among HIV-infected, treatment-naı¨ve African women,
initial NVP-based ART is as effective as LPV/r-based ART in
terms of virologic failure and death although more women in
the NVP arm discontinued treatment or developed new drug
resistance than in the LPV/r arm. Several limitations of this
study may affect the accuracy of these findings. In particular,
some of the study participants may have been exposed to
single-dose NVP during childbirth to prevent mother-to-child
transmission of HIV; in a parallel randomized trial, the
researchers found that LPV/r-based ART was superior to NVP-
based ART among women with prior exposure to single-
dose NVP. Moreover, the duration of the current study
means the long-term effects of the two treatments cannot
be compared. Nevertheless, these findings support the WHO
recommendation of NVP-based ART with careful early
toxicity monitoring as an initial affordable and effective HIV
treatment regiment in resource-limited settings, until access
to better-tolerated and more potent regimens is possible.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001236.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on all aspects of HIV
infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS,
and summaries of recent research findings on HIV care and
treatment (in several languages)
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including detailed
information on HIV treatment and care (in English and
Spanish)
N WHO provides information about universal access to AIDS
treatment (in English, French and Spanish); its 2010 ART
guidelines can be downloaded
N More information about this trial, the OCTANE trial, is
available
N MedlinePlus provides detailed information about
nevirapine and lopinavir/ritinovir (in English and Spanish)
N Patient stories about living with HIV/AIDS are available
through Avert; the nonprofit website Healthtalkonline also
provides personal stories about living with HIV, including
stories about taking anti-HIV drugs and the challenges of
anti-HIV drugs
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